All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
158 results
A multi-institutional, phase IV project to study the feasibility of safely managing patients receiving induction with liposomal daunorubicin and cytarabine (CPX-351) for acute myeloid leukemia (AML) in an outpatient environment
Outpatient Patients Receiving Induction With Liposomal Daunorubicin & Cytarabine (CPX-351) for AML
Protocol No
IIT-MICHAELIS-OUTPT-CPX-351
Sub Category
Hematologic/Blood Related Cancers
A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as having CDK Pathway Alteration
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Protocol No
IIT-CHARLSON-BOAST
Sub Category
Sarcoma
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
Hematologic/Blood Related Cancers
Phase 1 Study of Nivolumab in Combination with Tocilizumab for Treatment of Patients with Relapsed Hematological Malignancy Post-Allogeneic Transplant
Nivolumab in Combination with Tocilizumab for Patients with Relapsed Hematological Malignancy post Bone Marrow Transplant
Protocol No
IIT-SHAH-TOCI4-NIVOLUMAB
Sub Category
Hematologic/Blood Related Cancers
A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)
A SU2C Catalyst® Trial of a PD1 Inhibitor +/- Vitamin D Analog for the Maintenance of of Pancreatic Cancer
Protocol No
TGEN-17-001-SU2C-CATALYST
Sub Category
Gastrointestinal Cancers
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
PRospective Observational Multiple Myeloma Impact Study
Protocol No
SKYLINE-PROMMIS-MM
Sub Category
Hematologic/Blood Related Cancers
A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
We want to find out what effects, good and/or bad, the drug combination of brentuximab vedotin and ipilimumab used together at different dose levels have on you and your relapsed or refractory Hodgkin lymphoma.
Protocol No
ECOG-E4412
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Protocol No
ASTRAZENECA-D081SC00001-PROPEL
Sub Category
Prostate and Urologic Cancers
REPRISE IV
REPRISE IV is a prospective, multicenter single-arm study designed to evaluate the safety and effectiveness of the LOTUS Edge Valve System for TAVR in symptomatic subjects who have severe native aortic stenosis and are considered at intermediate risk for surgical valve replacement.
Primary Investigator: Michael Salinger, MD
Subinvestigators: Peter Mason, MD; Paul Pearson, MD; Joshua Meskin, MD
ClinicalTrials.gov Identifier: NCT03618095
Status: Currently Enrolling
Sub Category
Heart Valve Disease
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Effect of Palbociclib with Ovarian Suppression and Letrozole in Neoadjuvant Treatment of Breast Cancer
Protocol No
NSABP-FND-FB-13
Sub Category
Breast Cancers
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Protocol No
ALLIANCE-A021502-ATOMIC
Sub Category
Gastrointestinal Cancers
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (LUNG-MAP Sub-study)
Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation NSCLC
Protocol No
SWOG-LUNGMAP-S1900A
Sub Category
Thoracic Cancers
A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Protocol No
DECIPHERA-DCC-2618-03-002
Sub Category
Gastrointestinal Cancers
Sarcoma
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
Hematologic/Blood Related Cancers
A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (Transcend-Pilot-017006)
Protocol No
JUNO-JCAR017-017006
Sub Category
Hematologic/Blood Related Cancers